Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499

M. R. Smith, F. Hong, H. Li, L. I. Gordon, R. D. Gascoyne, E. M. Paietta, R. H. Advani, A. Forero-Torres, S. J. Horning, B. S. Kahl

Research output: Contribution to journalLetter

6 Scopus citations
Original languageEnglish (US)
Pages (from-to)517-519
Number of pages3
JournalLeukemia
Volume31
Issue number2
DOIs
StatePublished - Feb 1 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Smith, M. R., Hong, F., Li, H., Gordon, L. I., Gascoyne, R. D., Paietta, E. M., Advani, R. H., Forero-Torres, A., Horning, S. J., & Kahl, B. S. (2017). Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia, 31(2), 517-519. https://doi.org/10.1038/leu.2016.305